Literature DB >> 12553000

p63 expression profile in normal and malignant prostate epithelial cells.

Leland D Davis1, Wei Zhang, Axel Merseburger, Denise Young, Linda Xu, Johng S Rhim, Judd W Moul, Shiv Srivastava, Isabell A Sesterhenn.   

Abstract

p63 expression was evaluated in a tissue microarray of prostate tissues including benign glands, prostatic intraepithelial neoplasia and prostatic carcinoma. Immunostaining with anti-p63 antibody was restricted to basal cell nuclei. Detectable p63 was found in immortalized and early passage cell cultures, but not in senescent cultures or metastatic tumor-derived cell lines. The selective presence of p63 in basal cells of the prostate suggests that p63 can be used as a marker of basal cells and in vitro typing cell cultures of prostate cancer (CaP). The basal cell association underscores its critical functions in the biology of basal cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12553000

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Tissue microarrays: applications in urological cancer research.

Authors:  A S Merseburger; A G Anastasiadis; J Hennenlotter; D Schilling; P Simon; S A Machtens; J Serth; A Stenzl; M A Kuczyk
Journal:  World J Urol       Date:  2006-08-09       Impact factor: 4.226

2.  Periacinar retraction clefting and d2-40 expression in prostatic adenocarcinoma.

Authors:  Monika Ulamec; Tihana Džombeta; Hrvoje Cupić; Tanja Leniček; Davor Tomas; Božo Krušlin
Journal:  Pathol Oncol Res       Date:  2011-09-13       Impact factor: 3.201

3.  Periacinar Clefting and p63 Immunostaining in Prostatic Intraepithelial Neoplasia and Prostatic Carcinoma.

Authors:  Bozo Kruslin; Davor Tomas; Aida Cviko; Hrvoje Cupic; Ljubica Odak; Mladen Belicza
Journal:  Pathol Oncol Res       Date:  2006-12-25       Impact factor: 3.201

4.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

5.  SCC-112 gene is involved in tumor progression and promotes the cell proliferation in G2/M phase.

Authors:  M Z Zheng; L M Zheng; Y X Zeng
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-11       Impact factor: 4.553

6.  The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection.

Authors:  Can Guo; Zhi-Gang Pan; Da-Jiang Li; Jing-Ping Yun; Mei-Zhen Zheng; Zhe-Yu Hu; Li-Zhen Cheng; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2006-05-29       Impact factor: 5.531

7.  Nuclear iASPP may facilitate prostate cancer progression.

Authors:  E V Morris; L Cerundolo; M Lu; C Verrill; F Fritzsche; M J White; G N Thalmann; C S ten Donkelaar; I Ratnayaka; V Salter; F C Hamdy; X Lu; R J Bryant
Journal:  Cell Death Dis       Date:  2014-10-23       Impact factor: 8.469

8.  Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.

Authors:  Giorgio Mauri; Elena Jachetti; Barbara Comuzzi; Matteo Dugo; Ivano Arioli; Silvia Miotti; Sabina Sangaletti; Emma Di Carlo; Claudio Tripodo; Mario P Colombo
Journal:  Oncotarget       Date:  2016-01-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.